Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).
Faron Pharmaceuticals with Interim CFO
AppointmentsFinnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.
AmphiStar BV secures €6m to expand production
Latest NewsWaste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).
Naobios and Sumagen partner to develop HIV vaccine
Latest NewsVaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.
Solar Foods starts Factory01
Latest NewsFinnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.
Shock: Adrenomed AG gets FDA fast track designation
Latest NewsGerman AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity.
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Latest NewsALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Latest NewsALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Essential Pharma acquires Renaissance Pharma Ltd
Latest NewsEssential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.
Unitaid awards Medincell US$6m to fight malaria
Latest NewsGlobal health agency Unitaid has awarded French Medincell Corp (Jacou) an extension grant of up to US$ 6 million over three years to fund thesatety testing of its malaria vaccine mdc-STM.
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
Latest NewsGenmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).